1. Which of the following statements is TRUE about the United States before a change made in 2014?
A. In 2014, the most commonly prescribed opioid was hydrocodone
B. Women are more likely to abuse opioids than men
C. Patients with psychiatric disorders were not more likely to abuse prescription opioids
D. Marijuana use is second to opioid abuse in the United States
2. Which of the following pairing is correct?
A. Kappa receptors – hallucinations
B. Mu receptors – euphoria, physical dependence, supraspinal analgesia
C. Delta receptors – miosis, respiratory depression
D. NMDA receptors – dysphoria, bradycardia, hypothermia
3. Likability/attractiveness of opioids is influenced by all of the following EXCEPT:
A. Media attention
B. Low attractiveness quotient (low Cmax , high Tmax )
C. Tampering susceptibility
D. Peer preferences
4. Which of the following are considered standard risk mitigation strategies used in chronic pain?
A. Risk assessment tools (COMM, SOAPP-R)
B. Urine drug screens
C. Opioid treatment agreements
D. All of the above
5. Embeda and Suboxone are examples of which type of abuse-deterrent formulation approach?
A. Physical barrier
B. Viscosity management
C. Sequestered antagonist
D. Aversion agent
6. When ideally optimized from an efficacy standpoint, what two pharmacokinetic properties increase abuse potential?
A. Half-life, elimination factor
B. Cmax , Tmin
C. Receptor binding affinity, excretion factor
D. Cmin , and Tmin
7. Abuse-deterrent formulations would be useful in all of the following target populations EXCEPT:
A. Patients with history of substance abuse
B. Patients who are active substance abusers
C. Older patients
D. Homeless patients
8. Which of the following are considered limitations to using abuse-deterrent formulations?
A. Cost of health care
B. Reduced formulation options
C. Reduced routes of administration
D. All of the above
9. Which of the following is NOT an example of a strategy to reduce abuse potential?
A. Development of a pro-drug requiring metabolism in the gut to be activated
B. Pairing a medication with a secondary medication that has an aversive ingredient
C. Addition of a secondary ingredient that prevents parenteral use
D. Development of sustained- or delayed-release formulations
10. Which of the following would be included the FDA's categories for abuse-deterrent formulations?
A. Retesting and relabeling for a new indication
B. Reformulation for capsule contents to be used as a liquid for the same indication
C. New dosage range tested for renally impaired patients
D. Agonist/antagonist combination to help interfere with abuse
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. To what extent did the program meet objective #5?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
23. Will the information presented cause you to change your practice?
A. Yes
B. No
24. Are you committed to making these changes?
A. Yes
B. No
25. As a result of this activity, did you learn something new?
A. Yes
B. No
26. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
27. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20
E. >20
